Every 10-Q that Immunic, Inc. (IMUX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMUX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMUX filings page.
Immunic, Inc., a late-stage biotech developing oral therapies for neurologic and autoimmune diseases, reported higher operating expenses and losses for the quarter and six months ended June 30, 2026, driven mainly by Phase 3 development of vidofludimus calcium for multiple sclerosis and expanded stock-based compensation.
For the first half of 2026, operating expenses were $68.6 million versus $53.9 million a year earlier, leading to a net loss of $66.7 million. Net cash used in operating activities was $48.3 million. A February 2026 private placement raised $200 million gross ($187.3 million net), lifting cash and cash equivalents to $155.1 million and turning stockholders’ equity from a deficit to positive $127.6 million. Management states these funds are expected to support operations beyond twelve months. A 1‑for‑10 reverse stock split became effective April 27, 2026, and extensive warrants, options and SARs create a sizable pool of potential future share issuance.
Immunic, Inc. reported a first-quarter 2026 net loss of $32.6 million, wider than the $25.5 million loss a year earlier, as operating expenses rose to $33.2 million driven mainly by research and development spending of $25.6 million.
Financing activity significantly strengthened the balance sheet. A February 2026 private placement of pre-funded and common warrants generated gross proceeds of $200 million and net proceeds of $187.3 million, lifting cash and cash equivalents to $186.6 million as of March 31, 2026, compared with $15.5 million at year-end 2025. Management states these funds are expected to support operations for more than twelve months.
The company also completed a 1-for-10 reverse stock split effective April 27, 2026, regained compliance with Nasdaq’s minimum bid price requirement, and continued advancing its late-stage pipeline, including Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis and a Phase 2 program in progressive multiple sclerosis.
Immunic, Inc. filed its Q3 2025 report, highlighting continued losses and liquidity pressure. The company reported a net loss of $25,579 for the quarter and $77,872 for the nine months ended September 30, 2025. Cash and cash equivalents were $35,132, while net cash used in operating activities reached $66,525 for the nine-month period.
Current liabilities were $30,079 against total stockholders’ equity of $10,499, down from $18,429 at year-end. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. During 2025, Immunic raised $60,661 from a May offering and $4,734 from an April offering to fund operations. The company also received a Nasdaq notice for failure to maintain the $1.00 minimum bid, with a compliance window through December 24, 2025. Immunic continues advancing late-stage oral therapies, including vidofludimus calcium in Phase 3 for relapsing multiple sclerosis.